Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. However, a challenging macroeconomic scenario continues to plague Globus Medical. The stock ...

Globus Medical GMED has seen impressive momentum in the past year, with its shares soaring 62.1%. It has significantly outperformed the industry’s 7.3% rise and the S&P 500 composite’s 24.8% gain.

The company’s merger with NuVasive is expected to generate significant synergies. Additionally, a strong liquidity position bodes well. Meanwhile, the impact of fierce competition raises ...

Consensus $2.5B. “2024 was an exceptional year of execution and achievement for Globus Medical (GMED). With the NuVasive merger, we believe we ...

The manufacturers Nuvasive said there was always risk in treating scoliosis and Magec had rebuilt families' lives. BBC Panorama has been working with the International Consortium of Investigative ...